Quibim adds cancer detection capability to QP-Prostate


Quibim has announced the release of an enhanced version of its QP-Prostate product. This latest version includes a cancer detection feature and has received FDA clearance, CE mark and UKCA mark, allowing it to be used in clinical settings in the US, Europe and the UK. The new functionalities, developed using biopsy outcomes as ground truth, aim to accelerate image processing, improve radiologists’ accuracy in identifying signs of cancer, and help them provide actionable data points to oncology departments.